| For: | Kaewdech A, Sripongpun P. Challenges in the discontinuation of chronic hepatitis B antiviral agents. World J Hepatol 2021; 13(9): 1042-1057 [PMID: 34630873 DOI: 10.4254/wjh.v13.i9.1042] |
|---|---|
| URL: | https://www.wjgnet.com/1007-9327/full/v13/i9/1042.htm |
| Number | Citing Articles |
| 1 |
Apichat Kaewdech, Phunchai Charatcharoenwitthaya, Teerha Piratvisuth. Asian Perspective on Hepatitis B Virus and Hepatitis C Virus Elimination. Viruses 2024; 17(1): 34 doi: 10.3390/v17010034
|
| 2 |
Apichat Kaewdech, Suraphon Assawasuwannakit, Pimsiri Sripongpun, Naichaya Chamroonkul, Pisit Tangkijvanich, Teerha Piratvisuth. Clinical Utility of SCALE-B to Predict Hepatitis B Virus Relapse, Hepatitis B Surface Antigen Loss After Antiviral Cessation in Asian Patients After 2-Year Follow-up. Frontiers in Medicine 2022; 9 doi: 10.3389/fmed.2022.859430
|
| 3 |
Natchaya Polpichai, Sakditad Saowapa, Pojsakorn Danpanichkul, Shu-Yen Chan, Leandro Sierra, Johanna Blagoie, Chitchai Rattananukrom, Pimsiri Sripongpun, Apichat Kaewdech. Beyond the Liver: A Comprehensive Review of Strategies to Prevent Hepatocellular Carcinoma. Journal of Clinical Medicine 2024; 13(22): 6770 doi: 10.3390/jcm13226770
|
| 4 |
Shulin Xia, Xiaomin He, Jianhe Gan, Jiachen Ding. Impact of PC/BCP Mutations on Seroconversion and Relapse in HBeAg-Positive Chronic Hepatitis B Patients Treated with Nucleoside Analogues. Infection and Drug Resistance 2025; : 5949 doi: 10.2147/IDR.S536426
|
